• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可比性限制会影响不同试剂批次的质量控制结果。

Commutability limitations influence quality control results with different reagent lots.

机构信息

Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA.

出版信息

Clin Chem. 2011 Jan;57(1):76-83. doi: 10.1373/clinchem.2010.148106. Epub 2010 Nov 19.

DOI:10.1373/clinchem.2010.148106
PMID:21097677
Abstract

BACKGROUND

Good laboratory practice includes verifying that each new lot of reagents is suitable for use before it is put into service. Noncommutability of quality control (QC) samples with clinical patient samples may preclude their use to verify consistency of results for patient samples between different reagent lots.

METHODS

Patient sample results and QC data were obtained from reagent lot change verification records for 18 QC materials, 661 reagent lot changes, 1483 reagent lot change-QC events, 82 analytes, and 7 instrument platforms. The significance of between-lot differences in the results for QC samples compared with those for patient samples was assessed by a modified 2-sample t test adjusted for heterogeneity of QC and patient sample measurement variances.

RESULTS

Overall, 40.9% of reagent lot change-QC events had a significant difference (P < 0.05) between results for QC samples compared with results for patient samples between 2 reagent lots. For QC results with differences <1.0 SD interval (83.1% of total), 37.7% were significantly different from the changes observed for patient samples. For QC results with differences ≥1.0 SD interval (16.9% of total), 57.0% were significantly different from those for patient samples.

CONCLUSIONS

Occurrence of noncommutable results for QC materials was frequent enough that the QC results could not be used to verify consistency of results for patient samples when changing lots of reagents.

摘要

背景

良好的实验室规范包括在试剂投入使用前验证每批新试剂是否适用。质控(QC)样本与临床患者样本的不可互换性可能会阻止它们用于验证不同试剂批次之间患者样本结果的一致性。

方法

从 18 种 QC 材料、661 个试剂批次变化、1483 个试剂批次变化-QC 事件、82 个分析物和 7 个仪器平台的试剂批次变化验证记录中获得患者样本结果和 QC 数据。通过调整 QC 和患者样本测量方差异质性的改良两样本 t 检验评估 QC 样本结果与患者样本结果之间批间差异的显著性。

结果

总体而言,40.9%的试剂批次变化-QC 事件在 2 个试剂批次之间的 QC 样本结果与患者样本结果之间存在显著差异(P<0.05)。对于差异<1.0 SD 间隔(总差异的 83.1%)的 QC 结果,有 37.7%与患者样本观察到的变化显著不同。对于差异≥1.0 SD 间隔(总差异的 16.9%)的 QC 结果,有 57.0%与患者样本的结果显著不同。

结论

QC 材料不可互换的结果发生频率足够高,以至于在更换试剂批次时,QC 结果不能用于验证患者样本结果的一致性。

相似文献

1
Commutability limitations influence quality control results with different reagent lots.可比性限制会影响不同试剂批次的质量控制结果。
Clin Chem. 2011 Jan;57(1):76-83. doi: 10.1373/clinchem.2010.148106. Epub 2010 Nov 19.
2
Statistical validation of reagent lot change in the clinical chemistry laboratory can confer insights on good clinical laboratory practice.临床化学实验室中试剂批次变更的统计验证可为良好临床实验室规范提供见解。
Ann Clin Biochem. 2014 Nov;51(Pt 6):688-94. doi: 10.1177/0004563214520749. Epub 2014 Feb 4.
3
Centralization of multisite reagent lot-to-lot validation for Ortho Clinical Vitros chemistry instruments.多站点试剂批批验证的集中化管理:奥林巴斯临床化学仪器
Clin Biochem. 2021 Nov;97:62-66. doi: 10.1016/j.clinbiochem.2021.07.017. Epub 2021 Jul 31.
4
Evaluation of the CLSI EP26-A protocol for detection of reagent lot-to-lot differences.用于检测试剂批次间差异的CLSI EP26-A方案评估。
Clin Biochem. 2017 Sep;50(13-14):768-771. doi: 10.1016/j.clinbiochem.2017.03.012. Epub 2017 Mar 18.
5
Establishing a simple and sustainable quality assurance program and clinical chemistry services in Eritrea.
Clin Chem. 2007 Nov;53(11):1945-53. doi: 10.1373/clinchem.2007.093039.
6
Sample size and rejection limits for detecting reagent lot variability: analysis of the applicability of the Clinical and Laboratory Standards Institute (CLSI) EP26-A protocol to real-world clinical chemistry data.检测试剂批间差异的样本量和拒绝限:对临床和实验室标准协会(CLSI)EP26-A 方案在真实临床化学数据中适用性的分析。
Clin Chem Lab Med. 2020 Jul 6;59(1):127-138. doi: 10.1515/cclm-2020-0454.
7
Statistical assessment of DNA extraction reagent lot variability in real-time quantitative PCR.实时定量 PCR 中 DNA 提取试剂批次变异性的统计评估。
Lett Appl Microbiol. 2010 Mar;50(3):276-82. doi: 10.1111/j.1472-765X.2009.02788.x. Epub 2009 Dec 15.
8
The Importance of Reagent Lot Registration in External Quality Assurance/Proficiency Testing Schemes.试剂批次登记在外来质量保证/能力验证方案中的重要性。
Clin Chem. 2016 May;62(5):708-15. doi: 10.1373/clinchem.2015.247585. Epub 2016 Mar 15.
9
Research and discussion on the evaluation scheme of reagent lot-to-lot differences in 16 chemiluminescence analytes, established by the EP26-A guidelines of the CLSI.CLSI EP26-A 指南建立的 16 项化学发光分析物试剂批间差评价方案的研究与探讨。
J Clin Lab Anal. 2021 Mar;35(3):e23675. doi: 10.1002/jcla.23675. Epub 2020 Dec 3.
10
Failure of current laboratory protocols to detect lot-to-lot reagent differences: findings and possible solutions.现行实验室方案未能检测到批间试剂差异:发现与可能的解决方案。
Clin Chem. 2013 Aug;59(8):1187-94. doi: 10.1373/clinchem.2013.205070. Epub 2013 Apr 16.

引用本文的文献

1
Behind the scenes of EQA-characteristics, capabilities, benefits and assets of external quality assessment (EQA).EQA的幕后故事——外部质量评估(EQA)的特点、能力、益处和优势
Clin Chem Lab Med. 2025 Jan 6;63(5):879-897. doi: 10.1515/cclm-2024-1292. Print 2025 Apr 28.
2
[Not Available].[无可用内容]。
Adv Lab Med. 2024 Apr 15;5(2):153-158. doi: 10.1515/almed-2023-0147. eCollection 2024 Jun.
3
Calibration - an under-appreciated component in the analytical process of the medical laboratories.校准——医学实验室分析过程中一个未得到充分重视的组成部分。
Adv Lab Med. 2023 Nov 13;5(2):148-152. doi: 10.1515/almed-2023-0127. eCollection 2024 Jun.
4
Application of Patient-Based Real-Time Quality Control Based on Artificial Intelligence Monitoring Platform in Continuously Quality Risk Monitoring of Down Syndrome Serum Screening.基于人工智能监测平台的患者实时质量控制在唐氏综合征血清筛查持续质量风险监测中的应用。
J Clin Lab Anal. 2024 Mar;38(5):e25019. doi: 10.1002/jcla.25019. Epub 2024 Mar 11.
5
International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls.国际血液学标准化委员会关于凝血试剂、校准品和质控品新批号验证的指南。
Semin Thromb Hemost. 2024 Nov;50(8):1091-1102. doi: 10.1055/s-0043-1776405. Epub 2023 Nov 15.
6
Lot verification practices in Ontario clinical chemistry laboratories - Results of a patterns-of-practice survey.安大略省临床化学实验室的批次验证实践——实践模式调查结果
Pract Lab Med. 2022 Aug 10;32:e00300. doi: 10.1016/j.plabm.2022.e00300. eCollection 2022 Nov.
7
A study on quality control using delta data with machine learning technique.一项使用增量数据和机器学习技术进行质量控制的研究。
Heliyon. 2022 Jul 14;8(8):e09935. doi: 10.1016/j.heliyon.2022.e09935. eCollection 2022 Aug.
8
Assessment of patient based real-time quality control on comparative assays for common clinical analytes.基于患者的实时质量控制评估对常见临床分析物的比较分析。
J Clin Lab Anal. 2022 Sep;36(9):e24651. doi: 10.1002/jcla.24651. Epub 2022 Aug 10.
9
A comparative study on the effect of blood collection tubes on stress oxidative markers.采集管对压力氧化标记物影响的对比研究。
PLoS One. 2022 Apr 6;17(4):e0266567. doi: 10.1371/journal.pone.0266567. eCollection 2022.
10
Analysis of short-term variation and long-term drift during reagent kit lot change in an NABL accredited clinical biochemistry laboratory.NABL认可的临床生物化学实验室中试剂试剂盒批次更换期间的短期变化和长期漂移分析。
J Med Biochem. 2021 Jan 26;40(1):92-98. doi: 10.5937/jomb0-25597.